Patients’ Characteristics After HIFU Ablation
| Characteristic | Data |
|---|---|
| n | 14 |
| PSA (ng/mL) | 2.83 ± 1.65 (0.02–5.79) |
| PSA density (ng/mL2) | 0.07 ± 0.04 (0.00–0.17) |
| PSA nadir (ng/mL) | 2.80 ± 1.48 (0.01–5.79) |
| Time to PSA nadir (mo) | 6.55 ± 5.92 (2.90–24.83) |
| Biopsy (n = 13) | |
| Residual lesions | |
| Clinically significant | 1 |
| Clinically insignificant | 3 |
| Recurrent lesions | |
| Clinically significant | 3 |
| Clinically insignificant | 6 |
| 68Ga-PSMA11 | |
| Injected activity (MBq) | 145.60 ± 37.75 (82.51–221.26) |
| Uptake time (min) | 47.50 ± 2.40 (41.00–49.00) |
| Length of PET/MRI (min) | 45.50 ± 5.90 (33.00–62.00) |
| Delay to pelvic PET/MRI (min) | 26.00 ± 6.53 (22.00–48.00) |
| 68Ga-RM2 | |
| Injected activity (MBq) | 139.77 ± 5.04 (133.32–149.67) |
| Uptake time (min) | 46.00 ± 3.14 (39.00–52.00) |
| Length of PET/MRI (min) | 51.50 ± 9.53 (41.00–73.00) |
| Delay to pelvic PET/MRI (min) | 26.00 ± 6.22 (21.00–47.00) |
| Time between scans (d) | 5.00 ± 40.66 (2.00–172.00) |
| Time between pre- and post-HIFU scans (mo) | 7.43 ± 2.37 (5.93–12.60) |
Qualitative data are number and percentage; continuous data are median ± SD and range.